Myung In Haloperidol

Haloperidol

Schizophrenia, mania, psychotic disorder manifestations, Gilles de la Tourette's syndome, vomiting & hiccup.

Adult & childn (>14 yr) Initially 1-1.5 mg bd or tds. Maintenance: 2-8 mg daily. Severe patient Max: 100 mg daily.

May be taken with or without food: May be taken w/ meals to minimise GI irritation.

Hypersensitivity to haloperidol & butyrophenone. Comatose states, alcoholism; severe heart failure, Parkinson's disease, bronchopneumonia, basal ganglia lesions. Concomitant use w/ barbiturates, anesth & other CNS depressants; epinephrine. Women of childbearing potential. Pregnancy & lactation.

Phaeochromocytoma, CV disease, hypotension or conditions predisposing to this symptom. Epilepsy & conditions predisposing to convulsions (eg, alcohol w/drawal & brain damage) or history of seizure. Hyperthyroidism or hypothyroidism. Patients w/ physical damage accompanied w/ dehydration & malnutririon. Depression. QT syndrome & hypokalaemia. Patients receiving anticoagulants. Prolactin-dependent tumor; narrow angle glaucoma; severe myasthenia gravis; prostamegaly. Monitor liver & renal function, & blood cells during long-term treatment. May conceal emesis caused by other medicinal poisoning, intestinal obstruction & encephaloma. Gradual dose reduction is recommended. May affect the ability to drive & operate machinery. Hepatic & renal failure. Extrapyramidal reactions especially dyskinesia may occur easily in childn. Elderly.

ECG abnormality (QT-interval prolongation, (T-wave changes), lowering of BP, HTN, tachycardia, atypical ventricular tachycardia (including torsades de pointes); akinesia, severe muscle rigidity, dysdipsia, tachycardia, irregular pulse or BP, diaphoresis; acute dystonia, torticollis, mouth movements, dysphagia, parkinsonian rigidity, tremor, akathisia, lack of ability to sit in triangle; tardive dyskinesia; hepatitis, jaundice, impaired liver function; paropsis, retinitis, cataract, accommodation disturbances & blurred vision; edema, rash, urticaria, exfoliative dermatitis, photosensitivity & anaphylaxis; anemia, leukocytosis, leucopenia, aglobulia & agranulocytosis; anorexia, nausea, vomiting, constipation, & diarrhea; hyperprolactinaemia, gynecomastia, lactation, menstrual irregularities & libido changes, hyperglycemia, hypoglycemia, wt increase or decrease; bronchospasm, laryngospasm & dyspnea; insomnia, restlessness, drowsiness, vertigo, headache, anxiety, depression, hallucination & agitation; dry mouth, stuffy nose, fatigue, anuresis, pyrexia, diaphoresis & flush.

Concomitant use of haloperidol & CNS depressants (eg, analgesics & barbiturates, hypnotics, strong anesth, sedative, antihistamine, hypotensive & anticholinergic drug) & alcohol may potentiate the interaction. May antagonize action of epinephrine & other sympathomimetic agents & reverse the BP lowering effects of adrenergic-blocking agents (eg, guanethidine & clonidine). Decreased antiparkson effect of levodopa. Enhanced CNS effect w/ methyldopa. ECG pattern changes, severe extraphyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome (NMS), irreversible brain damage w/ lithium. Decreased plasma levels w/ enzyme inducing drugs (eg, carbamazepine & phenobarb). Inhibited metabolism of TCAs. Prolonged QT ventricular arrhythmia w/ terfenadine & astemizole. Mild to moderately increased levels w/ quinidine, buspirone & fluoxetine. Tardive dyskinesia w/ antiparkinson agent. Decreased therapeutic effects w/ antacid & caffeine.

Antipsychotics

N05AD01 - haloperidol ; Belongs to the class of butyrophenone derivatives antipsychotics.

POM